Syntimmune Closes $50 Million Series B Financing led by Apple Tree Partners
Syntimmune, Inc., a clinical-stage biotechnology company focused on FcRn biology, today announced a $50 million Series B financing led by Apple Tree Partners, which has committed $48 million to the round, with additional participation from other existing investors. The funds from the Series B financing will further advance Syntimmune’s clinical development program.
Printed from https://innovationblog.partners.org/syntimmune-closes-50-million-series-b-financing-led-apple-tree-partners · Published 07 Nov 2018
© PARTNERS HEALTHCARE. ALL RIGHTS RESERVED